Teofila Seremet
Teofila Seremet
Dermatologist, Université Libre de Bruxelles, Belgium
Verified email at erasme.ulb.ac.be
Cited by
Cited by
Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases
A Cipponi, M Mercier, T Seremet, JF Baurain, I Théate, J van den Oord, ...
Cancer research 72 (16), 3997-4007, 2012
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm …
M Schreuer, Y Jansen, S Planken, I Chevolet, T Seremet, V Kruse, ...
The Lancet Oncology 18 (4), 464-472, 2017
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
M Schreuer, G Meersseman, S Van Den Herrewegen, Y Jansen, ...
Journal of translational medicine 14 (1), 1-11, 2016
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
YJL Jansen, EA Rozeman, R Mason, SM Goldinger, MHG Foppen, ...
Annals of Oncology 30 (7), 1154-1161, 2019
Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy
T Seremet, F Brasseur, PG Coulie
The Cancer Journal 17 (5), 325-330, 2011
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
T Seremet, Y Jansen, S Planken, H Njimi, M Delaunoy, H El Housni, ...
Journal of translational medicine 17 (1), 1-13, 2019
Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib
YJ Jansen, P Janssens, A Hoorens, MS Schreuer, T Seremet, ...
Melanoma research 25 (6), 550-554, 2015
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
T Seremet, A Koch, Y Jansen, M Schreuer, S Wilgenhof, V Del Marmol, ...
Journal of translational medicine 14 (1), 1-14, 2016
Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma
R Váraljai, K Wistuba-Hamprecht, T Seremet, JMS Diaz, J Nsengimana, ...
JCO Precision Oncology 3, 1-10, 2019
Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma
N Sundahl, T Seremet, J Van Dorpe, B Neyns, L Ferdinande, A Meireson, ...
International Journal of Radiation Oncology* Biology* Physics 104 (4), 828-835, 2019
Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases
YJL Jansen, G Verset, K Schats, PJ Van Dam, T Seremet, M Kockx, ...
ESMO Open 4 (2), e000464, 2019
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from …
T Seremet, S Planken, M Schreuer, Y Jansen, M Delaunoy, H El Housni, ...
Melanoma research 28 (1), 65-70, 2018
Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma
M Schreuer, G Meersseman, S van Den Herrewegen, Y Jansen, ...
Melanoma research 26 (2), 157-163, 2016
Successful (neo) adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma
T Seremet, D Lienard, M Suppa, AL Trepant, S Rorive, E Woff, N Cuylits, ...
Melanoma research 25 (2), 180-183, 2015
Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma
T Seremet, S Planken, JK Schwarze, Y Jansen, L Vandeweerd, ...
Melanoma research 29 (1), 85-88, 2019
Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition
G Awada, T Seremet, K Fostier, H Everaert, B Neyns
Blood advances 2 (16), 2156-2158, 2018
Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure
MS Schreuer, IL Chevolet, YJ Jansen, TC Seremet, S Wilgenhof, ...
Melanoma research 25 (1), 68-74, 2015
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV …
Y Jansen, V Kruse, J Corthals, K Schats, PJ van Dam, T Seremet, ...
Cancer Immunology, Immunotherapy 69 (12), 2589-2598, 2020
Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test
T Seremet, A Haccuria, D Lienard, V del Marmol, B Neyns
Melanoma research 29 (1), 95-98, 2019
The predictive and prognostic significance of cell‐free DNA concentration in melanoma
R Váraljai, S Elouali, SS Lueong, K Wistuba‐Hamprecht, T Seremet, ...
Journal of the European Academy of Dermatology and Venereology 35 (2), 387-395, 2021
The system can't perform the operation now. Try again later.
Articles 1–20